Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial P. Germonpré, A. Janssens, L. Van Moorter, D. Verresen, D. Galdermans, R. Devogelaere, H. Ottevaere, Y. Menstens, C. De Pooter, C. Goor (Antwerp, Aalst, Wilrijk, Oostende, Oudenaarde, Herentals, Belgium)
Source: Annual Congress 2008 - Therapy in thoracic oncology
Session: Therapy in thoracic oncology Session type: Oral PresentationNumber: 1552
Disease area: Thoracic oncologyRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Germonpré, A. Janssens, L. Van Moorter, D. Verresen, D. Galdermans, R. Devogelaere, H. Ottevaere, Y. Menstens, C. De Pooter, C. Goor (Antwerp, Aalst, Wilrijk, Oostende, Oudenaarde, Herentals, Belgium). Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial. Eur Respir J 2008; 32: Suppl. 52, 1552
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) versus gemcitabine (G) or paclitaxel (T) alone in elderly or unfit nonsmall cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Phase II trial on neoadjuvant chemoradiation with paclitaxel/carboplatin in stage III NSCLC Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment Year: 2003
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001
A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007